Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

EMA Starts Review of Tredaptive, Pelzont, Trevaclyn Medicines

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/21/2012 | 11:46am CEST

LONDON--The European Medicines Agency, or EMA, Friday said it has started a review of the safety and efficacy of Tredaptive, Pelzont and Trevaclyn, identical medicines that are used to treat adults with dyslipidaemia, particularly combined mixed dyslipidaemia and primary hypercholesterolaemia.

MAIN FACTS:

-Review was triggered because the Agency was informed by the pharmaceutical company Merck, Sharp & Dohme of the preliminary results of a large, long-term study comparing the clinical effects of adding these medicines to statins (standard medicines used to reduce cholesterol) with statin treatment alone.

-Study raises questions about the efficacy of the medicine when added to statins, as this did not reduce the risk of major vascular events compared with statin therapy alone.

-Preliminary results saw a higher frequency of non-fatal but serious side effects in patients taking the medicines than in patients only taking statins.

-Pharmacovigilance Risk Assessment Committee (>> PRODUCTIVITY TECHS CORP) will assess the data and make a recommendation to the Committee on Medicinal Products for Human Use (>> Champion Industries, Inc.), which will issue an opinion on the regulatory action required.

-Opinion is expected in January 2013.

-Write to Tapan Panchal at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : PRODUCTIVITY TECHS CORP, Champion Industries, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
06/22 MERCK AND : Premier Inc. Expand Collaboration to Address Chronic Care and Vaccin..
06/21 LEAP THERAPEUTICS : Announces Collaboration with Merck
06/20 GENEXINE : Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Thera..
06/15 INCYTE : Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination..
06/15 MERCK AND : StayWell To Host Webinar For Hospital And Health System Leaders On D..
06/15 Telephus Medical CEO Mark Benedyk Joins Pulmotect, Inc. Board of Directors
06/13 MERCK & CO : ex-dividend day
06/12 MERCK : Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTR..
06/10 MERCK AND : Pfizer Announce that Investigational SGLT-2 Inhibitor Ertugliflozin ..
06/06 Drug Delivery Technologies Market 2017 - Sanofi, 3M Company, Bayer AG, Novart..
More news
Sector news : Pharmaceuticals - NEC
12:18p FTSE struggles one year on from Brexit, haunted by uncertainty
06/22 GSK'S NEW CEO AIMS TO DIVEST SPORTS : sources
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 Bullish On Ziopharm
06/21 Biotechs ripping, IBB up almost 8% in three days
Advertisement
Financials ($)
Sales 2017 39 964 M
EBIT 2017 13 664 M
Net income 2017 7 128 M
Debt 2017 3 171 M
Yield 2017 2,84%
P/E ratio 2017 25,42
P/E ratio 2018 19,23
EV / Sales 2017 4,60x
EV / Sales 2018 4,46x
Capitalization 180 576 M
More Financials
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 69,4 $
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY12.15%180 576
JOHNSON & JOHNSON17.10%366 496
NOVARTIS7.69%225 516
ROCHE HOLDING LTD.8.81%225 056
PFIZER4.86%202 832
SANOFI15.28%124 760
More Results